[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621234":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":45,"collaborators":11,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":11,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":11,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Atom Therapeutics Co., Ltd","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ABP-671","EXPERIMENTAL",null,[13],"Drug: ABP-671 plus allopurinol",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","ABP-671 plus allopurinol","All subjects undergo three sequential 7-day periods:\n\nPeriod 1 (Day 1-7): Allopurinol；\n\nPeriod 2 (Day 1-7): Allopurinol Plus ABP-671；\n\nPeriod 3 (Day 1-7): ABP-671；",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"MaoE Sun","CONTACT","13914017855","mao.e.sun@atombp.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Wakefield Clinical Research","RECRUITING","Cary","North Carolina","27560","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-78.78112,35.79154,{"lat":39,"lon":38},[42],{"name":43,"role":44,"phone":11,"phoneExt":11,"email":11},"Xiaohuan Li, MD","PRINCIPAL_INVESTIGATOR",{"type":46,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100621234","phase-1-drug-drug-interaction-study-of-abp-671-in-gout-patients-100621234",false,"NCT07367971","Drug-Drug Interaction Study of ABP-671 in Gout Patients","Open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients","Inclusion Criteria:\n\n* Adults 18-75 years with clinical diagnosis of gout.\n* Stable Allopurinol therapy QD for ≥14 days prior to Day 1.\n* Cohort N: Normal renal function.\n* Cohort R: Moderate renal impairment.\n\nExclusion Criteria:\n\n* Clinically significant hepatic impairment.\n* History of Allopurinol hypersensitivity.\n* Pregnancy or breastfeeding.","ALL","18 Years","75 Years",{"count":58,"type":59},20,"ESTIMATED","INTERVENTIONAL",[62],"PHASE1","This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.",[65,66,67],"Gout Chronic","Gout","DDI (Drug-Drug Interaction)",[69,65,9],"gout","2026-04-12",{"date":72,"type":73},"2026-04-14","ACTUAL",{"date":75,"type":73},"2026-01-23",{"date":77,"type":59},"2026-08-31",{"name":5,"class":6},1]